PMID- 36225282
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221014
IS  - 2287-8882 (Print)
IS  - 2287-903X (Electronic)
IS  - 2287-8882 (Linking)
VI  - 10
IP  - 3
DP  - 2022 Sep
TI  - Olaparib outcomes in metastatic castration-resistant prostate cancer: First 
      real-world experience in safety and efficacy from the Chinese mainland.
PG  - 142-147
LID - 10.1016/j.prnil.2022.04.005 [doi]
AB  - BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been 
      approved for use in breast cancer susceptibility gene (BRCA)-mutated metastatic 
      castration-resistant prostate cancer (mCPRC) patients. Our aim was to evaluate 
      the adverse events (AEs) and efficacy of Olaparib in the treatment of mCRPC 
      patients from the Chinese mainland. METHODS: We retrospectively included mCPRC 
      patients treated with Olaparib more than for 28 days. Patients with alterations 
      in 15 homologous recombination repair (HRR) genes were defined as the HRRmt 
      group, and the rest were defined as the HRRwt group. The efficacy was analyzed by 
      prostate-specific antigen (PSA) decreased rate and PSA progression-free survival 
      (PFS). The partial response, good response, and high response of PSA were defined 
      as a reduction of between 0% and 50%, greater than 50%, and greater than 90% from 
      baseline. RESULTS: A total of 43 patients were enrolled in this study, including 
      26 HRRmt group patients and 17 HRRwt group patients. Two HRRwt patients received 
      additional abiraterone therapy. A partial response, good response, and high 
      response were achieved in 89% (23/26), 59% (15/26), and 15% (4/26) of HRRmt group 
      patients, respectively. In HRRwt group, 59% (10/17), 35% (6/17), and 12% (2/17) 
      of patients met the criteria of partial response, good response, and high 
      response, respectively. Median PFS was 8.0 months in the HRRmt group and 
      3.0s months in the HRRwt group (HR, 0.61; 95% CI, 0.24-1.14; p = 0.148), 
      respectively. All the 20 patients had AEs during Olaparib treatment. Ten episodes 
      of grade 3 or 4 AEs were observed in four patients. The most common all-grade AEs 
      were fatigue or asthenia (70%), anemia (65%), and decreased appetite (55%). 
      CONCLUSIONS: Most of the AEs were tolerated, and Olaparib was effective in mCRPC 
      patients with HRR deficiency. In addition, the underlying mechanism of the 
      efficacy of Olaparib observed in HRRwt group patients remained explored.
CI  - (c) 2022 Asian Pacific Prostate Society. Published by Elsevier B.V.
FAU - Pan, Jian
AU  - Pan J
AD  - Department of Urology, Department of Oncology, Fudan University Shanghai Cancer 
      Center, Shanghai, China.
FAU - Ye, Dingwei
AU  - Ye D
AD  - Department of Urology, Department of Oncology, Fudan University Shanghai Cancer 
      Center, Shanghai, China.
FAU - Zhu, Yao
AU  - Zhu Y
AD  - Department of Urology, Department of Oncology, Fudan University Shanghai Cancer 
      Center, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220506
PL  - Korea (South)
TA  - Prostate Int
JT  - Prostate international
JID - 101605566
PMC - PMC9520412
OTO - NOTNLM
OT  - Efficacy
OT  - Olaparib
OT  - Prostate cancer
OT  - Safety
COIS- The authors have no conflicts of interest that are directly relevant to the 
      content of this article.
EDAT- 2022/10/14 06:00
MHDA- 2022/10/14 06:01
PMCR- 2022/05/06
CRDT- 2022/10/13 02:27
PHST- 2022/03/08 00:00 [received]
PHST- 2022/04/21 00:00 [revised]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/10/13 02:27 [entrez]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/10/14 06:01 [medline]
PHST- 2022/05/06 00:00 [pmc-release]
AID - S2287-8882(22)00022-8 [pii]
AID - 10.1016/j.prnil.2022.04.005 [doi]
PST - ppublish
SO  - Prostate Int. 2022 Sep;10(3):142-147. doi: 10.1016/j.prnil.2022.04.005. Epub 2022 
      May 6.